

Consensus guidelines for the safe prescription and administration of oral bowel-cleansing agents

Andrew Connor,¹ Damian Tolan,² Stephen Hughes,³ Nick Carr,⁴ Charles Tomson³

► Additional appendices are published online only. To view these files please visit the journal online (<http://dx.doi.org/10.1136/gutjnl-2011-300861>).

¹SpR, Dorset County Hospital, Dorchester, UK

²St James' University Hospital, Leeds, UK

³Southmead Hospital, Bristol, UK

⁴Singleton Hospital, Swansea, UK

Correspondence to

Dr Stephen Hughes, 43 Kellaway Avenue, Bristol BS6 7XS, UK; steve.hughes@nbt.nhs.uk

Accepted 2 May 2012

Published Online First
26 July 2012

ABSTRACT

Oral bowel-cleansing preparations are used before colonic surgery and endoscopic and radiological assessment of the intestine to minimise faecal contamination. In February 2009, the UK National Patient Safety Agency issued a Rapid Response Report highlighting the potential risk of harm associated with the use of these preparations and instructing local NHS Trusts to implement safeguards to reduce this risk. This guidance has been prepared to help NHS Trusts to respond to these concerns, as the risk of complications is influenced by both individual patient risk factors and the choice of bowel preparation, for which definitive guidance was not previously available. This document provides an outline of the different available oral bowel-cleansing agents and the complications that may arise. This is followed by recommendations for their use in different patient groups and circumstances. The recommendations are based on consensus between the authors, each of whom circulated drafts to members of their specialist society. The evidence for these recommendations has been assessed using the modified GRADE system. The recommendations cover the choice, administration and complications (relative and absolute) of the different oral bowel-cleansing agents, with specific guidance provided for different patient groups.

INTRODUCTION

Oral bowel-cleansing preparations are used before colonic surgery and endoscopic and radiological assessment of large and small intestine to minimise faecal contamination. In general, these preparations are safe and well tolerated. However, in February 2009, the UK National Patient Safety Agency (NPSA) issued a Rapid Response Report alerting healthcare providers to the potential risk of harm associated with the use of oral bowel-cleansing preparations and reporting one death and 218 patient safety incidents occurring over a 5-year period.¹ Six per cent of the 218 patient safety incidents resulted in moderate harm and one patient death was reported. These data are derived from a voluntary reporting system and, as such, are subject to bias: a proportion of incidents will not be reported, and those that are reported may underestimate severity (if reported before the full patient outcome is known). The majority of these incidents were reported as relating to the administration (56%) and prescription (21%) of the oral bowel-cleansing agents. The manifestations of these patient safety incidents included harm as a result of prescription of bowel preparation to patients in whom there was a definite contraindication (eg, presence of ileostomy, bowel obstruction)

or renal failure as a result of phosphate nephropathy, complications of hypovolaemia and electrolyte disturbances including hypokalaemia, hyponatraemia and hypermagnesaemia. Although there are no reliable estimates of the frequency of each of these complications, it is reasonable to put systems in place to reduce the risk of complications, so long as this response is proportionate and does not greatly add to the complexity or cost of investigation.

SCOPE

The NPSA Report instructed NHS Trusts that safeguards should be implemented at a local level to reduce this risk, and specifically required that all NHS Trusts ensure that a clinical assessment of each patient for contraindications and risks occurs, that the use of a bowel-cleansing preparation is authorised by a clinician, that an explanation on the safe use of the preparation is provided to the patient, and that a safe system exists for the supply of the preparation for each patient. This guidance has been prepared to help in the first of these recommendations relating to clinical assessment. We believe that guidelines are necessary because the risk of complications depends on the choice of bowel preparation and on risk factors present in the individual patient and there has been to date no definitive guidance on which preparation to use for which patients. These guidelines are therefore aimed at a UK audience but may have relevance to other countries. They are intended to be of benefit to those services prescribing and administering oral bowel-cleansing agents and to those clinicians referring patients for investigations and procedures that may require their use.

The guidelines do not include recommendations on incorporation of prescription of bowel-cleansing agents in the request for investigation, nor do they cover the use of oral bowel-cleansing agents in children or in pregnancy. The guidelines do not cover preparation for radiological or endoscopic examination of the small bowel.

These guidelines do not attempt to address the thorny issue of which bowel-cleansing agent is the most effective or which regimen for administration is most useful. It does not cover scoring systems to assess the efficacy of the preparation, split dosing or other attempts to improve the quality of the bowel cleansing. Although these issues are crucial to successful bowel examination, they are beyond the scope of this document.

Guidelines for bowel preparation before colonoscopy are already in existence, but they do not adequately address the risks identified by the NPSA.²

METHODOLOGY

The authors were put forward by their specialist societies to produce an initial draft. One author (AC) prepared an initial document (April 2009). This was informed by an exhaustive literature review. A formal systematic review was not undertaken, as the question that these guidelines seek to answer (how best to prescribe and administer oral bowel-cleansing agents, within different patient populations, while minimising the differing risks associated with the various preparations) was considered to be more complex than might effectively be answered through systematic literature review.

The initial document was reviewed by the other authors, revised individually, and a consensus draft agreed upon (June 2009). This was then circulated to the appropriate committees for review within each specialist society. The following committees were consulted: the Endoscopy Committee of the British Society of Gastroenterology; the Clinical Practice Guidelines Committee of the Renal Association; the British Society of Gastrointestinal and Abdominal Radiologists Committee and the Board of the Faculty of Clinical Radiology (for the Royal College of Radiologists); and the Clinical Services Committee of the Association for Coloproctology of Great Britain and Ireland (for The Royal College of Surgeons). The revised guidelines were then posted on the respective websites of the specialist societies as draft guidelines for further comment (early 2010), thereby allowing the guidelines to be available as interim guidance for members. Further revisions were made on the basis of feedback from members and after review by the Clinical Services and Standards Committee of the British Society of Gastroenterologists (late 2010), before submission of the guidelines for publication (January 2011).

In order to provide early draft guidance on the websites of the contributing groups according to the timescale imposed by the NPSA (requiring implementation of the recommendations in the Rapid Response Report by 7 September 2009), we have not performed a systematic review nor adhered in full to the guideline development methodology recommended by the National Institute for Health and Clinical Excellence (NICE). There was no representation from patient groups nor from the Pharmaceutical Industry. The companies that market the products discussed have not been consulted for their views and some of our recommendations go beyond the summary of product characteristics. The evidence for these recommendations has been assessed by the authors using the modified GRADE system.^{3 4} The modified GRADE system first defines the strength of the recommendations of guideline authors. Expert recommendations are graded as 'strong' (grade 1) or 'weak' (grade 2) balanced by benefits and risks, burden and cost. Second, the quality or level of evidence upon which the recommendation is based is designated as high (grade A), moderate (grade B), low (grade C) or very low (grade D), depending on study design and consistency of results. Grades of recommendation and quality of evidence may therefore range from 1A to 2D (see online appendix 1). We hope that NICE will develop guidelines to cover this topic in the near future.

BACKGROUND

Bowel-cleansing agents available for use

A number of different oral bowel-cleansing agents are currently available in the UK, including the following.⁵

- ▶ Citrafleet (De Witt, Warrington, UK); sodium picosulphate and magnesium citrate
- ▶ Citramag (Sanochemia, Bristol, UK); magnesium carbonate and citric acid

- ▶ Fleet Phospho-Soda (De Witt); sodium dihydrogen phosphate dehydrate and disodium phosphate dodecahydrate
- ▶ Klean Prep (Norgine, Uxbridge, UK); polyethylene glycol
- ▶ Moviprep (Norgine); polyethylene glycol
- ▶ Picolax (Ferring, West Drayton, UK); sodium picosulphate and magnesium citrate

The ideal oral bowel-cleansing agent would be convenient to administer, well tolerated, effective in cleansing, with an acceptable side-effect profile. No single agent is ideal in all clinical scenarios, and research into the ideal agent (or combination) continues. The different oral bowel-cleansing agents available in the UK are summarised in online appendix 2.

Polyethylene glycols (also known as PEG or macrogols) are non-absorbable iso-osmotic solutions, which pass through the bowel without net absorption or secretion. Significant fluid and electrolyte shifts are therefore attenuated. Moviprep contains 100 g polyethylene glycol, while Klean Prep contains 69 g. Both Moviprep and Klean Prep contain a balanced electrolyte solution, which reduces associated fluid and electrolyte disturbances. Moviprep also contains ascorbic acid, which contributes to the cathartic effect of the preparation. The preparations must be diluted in large volumes of water (up to 4 litres) to achieve the desired cathartic effect, and often have an unpalatable taste (despite flavourings). Compliance is better with divided-dose regimens (eg, the initial 2–3 litres on the night before the procedure and the remaining 1–2 litres the following morning).⁶ Not all of the ingested water stays within the gut lumen; absorption of water can therefore lead to water intoxication in predisposed patients.

Conversely, oral sodium phosphate preparations are hyperosmotic and promote colonic evacuation by drawing large volumes of water into the colon (1–1.8 litres of water per 45 ml of preparation).⁷ They are typically diluted in much smaller volumes of water than the polyethylene glycols (~250 ml).

Sodium phosphate preparations have been compared with polyethylene glycols in numerous studies and have generally been found to be safe, equally effective and consistently better tolerated.^{8–12} Two meta-analyses are of note. One meta-analysis of eight controlled trials concluded that, while an 'excellent' preparation was more likely with sodium phosphate preparations, 'adequate' preparation was equally likely with sodium phosphate or polyethylene glycol preparations.⁹ More recently, data regarding the quality of bowel preparation from 104 randomised controlled trials comparing bowel preparation regimens for colonoscopy were pooled in multiple meta-analyses exploring a range of inclusion criteria.¹³ Overall, no significant difference in the quality of bowel cleansing achieved with sodium phosphate and polyethylene glycol preparations was identified, although the latter were comparatively more efficacious in preparing the proximal bowel and also when previous-day regimens were used.

Picosulphate is a prodrug that is metabolised within the bowel lumen to a stimulant that promotes peristalsis. It is often combined with magnesium salts (eg, in Picolax or Citrafleet), which act synergistically through their osmotic effects.^{14 15} A dose sufficient to provide adequate bowel cleansing is usually diluted in a total of 300 ml of water. Data on efficacy of cleansing are mixed when compared with other agents.^{16–21} It remains widely used for bowel preparation for radiological procedures.^{22–25} One study of 72 patients over 70 years of age found that good overall bowel preparation was achieved in 88% of patients receiving Picolax before CT colonography.²⁶

Preparations of magnesium carbonate with citric acid, such as Citramag, are osmotic saline agents that require only 200 ml of water as a diluent. Magnesium salts are well tolerated and

effective, and have been reported to be used to prepare the bowel in one in every three colonoscopies undertaken in the UK.²⁷

Some types of bowel preparation leave a significant amount of watery residue in the gut lumen, which is not a problem for endoscopic or surgical procedures. However, this may interfere with mucosal visualisation at CT colonography and barium enema and these laxatives are usually avoided for radiological imaging. Picolax produces the 'driest' bowel, Citramag is intermediate, and polyethylene glycol preparations leave the highest amount of watery residue. The choice of agent therefore depends to some extent on which procedure the patient is being prepared for.

Bioavailability of some medications may be affected by bowel cleansing (eg, oral contraceptive pill). There is no evidence relating to bioavailability of immunosuppressive agents. Oral iron should be stopped at least 5 days before colonoscopy, as it forms an adherent residue that interferes with mucosal visualisation.

Diabetic glycaemic control, particularly in patients with type 1 diabetes, can be problematic during the period of dietary restriction, requiring individualised advice from local diabetic specialists. Admission for intravenous glucose and insulin may be required in a small number of cases.

Preparations vary in the requirement for dietary restrictions; most require that a clear liquid or low-residue diet should be followed for the 24 h or longer before the procedure, but with Fleet Phospho-Soda it is only necessary to avoid solid food during the dosing period.

Combinations of different bowel-cleansing agents (eg, Picolax and Klean Prep or combinations of senna granules with Citramag) are used in some centres²⁸; these regimens are beyond the scope of these guidelines.

Complications from bowel-cleansing agents

When administered correctly, all of the preparations listed have been demonstrated to be safe for use in healthy individuals without significant comorbidity, and to effect adequate bowel cleansing.^{8, 29–32} However, as hypertonic solutions, sodium phosphate preparations can cause major fluid and electrolyte shifts, and should generally be considered second-line agents that should only be prescribed to patients without other comorbidities (in particular, these preparations should be avoided in those with chronic kidney disease, congestive cardiac failure, liver failure, hypertension or patients taking renin–angiotensin blockers or diuretics).

Current practice for elective procedures is typically for patients to self-medicate with oral bowel-cleansing agents at home, often received through the post without formal screening of their comorbidities, medications or hydration state. While the practice of self-medication at home should remain feasible for the majority of patients, it is clear that a screening process is necessary to ensure that patients at risk of harm from oral bowel-cleansing agents are identified and prepared appropriately.

Hypovolaemia

Patients receiving oral bowel-cleansing agents are at risk of developing the complications of hypovolaemia and intravascular volume depletion—including syncope, myocardial ischaemia and acute kidney injury secondary to acute tubular necrosis. This risk is likely to be greatest with sodium phosphate preparations, but also exists with sodium picosulphate (although a recent study of 72 patients receiving Picolax before CT colonoscopy revealed no significant changes in estimated glomerular

filtration rate (GFR)²⁶); the risk of hypovolaemia is least with polyethylene glycol preparations.

Hypokalaemia

The frequency with which hypokalaemia occurs after oral bowel-cleansing preparations is variable. In studies of patients receiving sodium phosphate preparations, hypokalaemia has been reported to occur in 56% of older inpatients and 26% of unselected patients.^{33, 34} A retrospective study found the incidence of hypokalaemia (<3.0 mmol/l) in patients administered polyethylene glycol preparations before colonoscopy to be 9.6%.³⁵ Hypokalaemia can occur for two reasons after bowel preparation: increased gastrointestinal loss of secreted potassium complicating the use of hyperosmotic and stimulant preparations, and, with the use of sodium phosphate, increased urinary loss as a result of hyperphosphaturia.³⁶ Co-administration of a carbohydrate–electrolyte solution with sodium phosphate has been reported to reduce the risk of hypokalaemia.³⁷

Hyponatraemia

The ingestion of large volumes of water, particularly in the context of reduced free water clearance, also predisposes patients to hyponatraemia (a risk that was highlighted specifically in the NPSA Rapid Response Report). Polyethylene glycol preparations involve the ingestion of up to 4 litres of water, but are designed to be isotonic. The risk of hyponatraemia is probably highest when excessively large volumes of water are ingested (as a result of overzealous adherence to advice to 'drink plenty of fluids') to offset water loss into the colon caused by oral sodium phosphate and sodium picosulphate preparations.³⁸ Hyponatraemia has also been reported after use of polyethylene glycols, but is rare.³⁹ Reports of hyponatraemia occurring with magnesium-based agents are very rare.⁴⁰

Phosphate nephropathy

Acute phosphate nephropathy is an increasingly reported but underdiagnosed cause of chronic kidney disease,^{41, 42} which may occur in up to 1 in 1000 patients who receive sodium phosphate preparations.⁴¹ Oral sodium phosphate preparations provoke a transient mild hyperphosphataemia,⁸ which is most profound in older subjects.⁴³ This is rarely associated with untoward events and may reflect the normal reduction in GFR with advancing age. For this reason, the recommendations in this document are based on GFR and not on age. However, other factors that promote hyperphosphataemia predispose patients to acute phosphate nephropathy, such as inappropriate phosphate dosing, increased bowel transit time, and a reduced ability to excrete a phosphate load (such as renal impairment).⁴⁴ Factors promoting tubular precipitation of calcium phosphate also predispose to acute phosphate nephropathy and include inadequate hydration during phosphate administration, hypertension with arteriosclerosis, and medications including non-steroidal anti-inflammatory drugs (NSAIDs), diuretics and renin–angiotensin inhibitors.⁴² Heart failure, cirrhosis and advancing age are additional risk factors.^{45, 46}

Recent concerns over acute phosphate nephropathy are reflected in changes made to the availability of oral sodium phosphate preparations by the US Food and Drug Administration. These preparations are no longer available as over-the-counter medications for oral bowel cleansing, and those sodium phosphate preparations that are available as over-the-counter laxatives now carry a boxed warning.⁴⁷

Hypocalcaemia

Hypocalcaemia is a direct result of hyperphosphataemia and has been reported to occur in 58% of patients who receive oral sodium phosphate.³³ Hypoparathyroidism is a risk factor for severe hypocalcaemia in this situation.³⁶

Hypernatraemia

Hypernatraemia is uncommon, but can occur as a result of the sodium load in oral sodium phosphate preparations in combination with inadequate water intake.³⁶

Hypermagnesaemia

Those preparations containing magnesium salts (Picolax, Citrafleet and Citramag) can cause a transient rise in serum magnesium levels. They present a risk of hypermagnesaemia in patients with chronic kidney disease and can potentially lead to magnesium toxicity. A small number of such cases have been reported.^{48–50} The respective summary of product characteristics for each of the individual magnesium-based preparations advocates the use of alternative preparations in patients with 'severely reduced renal function'. In a recent study of 72 older patients with a mean estimated GFR of 60.8 ml/min per 1.73 m² and receiving sodium picosulphate with magnesium citrate (Picolax) before CT colonoscopy, serum magnesium levels were measured before and after the administration of Picolax in 14 patients.²⁶ Although without clinical sequelae in this study, three patients experienced an increase in serum magnesium in excess of 0.25 mmol/l.

Is a bowel-cleansing agent required?

Oral bowel-cleansing agents have traditionally been prescribed (predominantly on the basis of observational data and expert opinion) before elective colorectal surgery in an effort to reduce the likelihood of surgical complications arising from anastomotic leakage. However, opinion is increasingly divided on the merits of bowel preparation in this context. There is an increasing body of evidence to suggest that bowel preparation is not required for most procedures. Two recent trials are particularly noteworthy. First, in a trial randomising over 1300 patients, Jung *et al* found no appreciable difference in clinical anastomotic leaks and intra-abdominal abscesses between those patients receiving bowel preparation and those receiving no bowel preparation (2.6% vs 4.3%, effect difference 1.7%, 95% CI 0.7 to 2.7).⁵¹ Similar conclusions were reached by Contant *et al*, who randomised 1431 patients undergoing elective colorectal surgery to receive an oral bowel-cleansing agent (polyethylene glycol or oral sodium phosphate) or no bowel preparation.⁵² While the rate of intra-abdominal abscesses was slightly higher in the group not receiving bowel preparation (4.7% vs 2.2%, $p=0.02$), the general incidence was low. All other end points (mortality, length of hospital stay, re-intervention rate) were similar among the two groups.

At present, patients who undergo abdominoperineal excision of the rectum, right hemicolectomy, total proctocolectomy and ileoanal pouches are generally not prescribed oral bowel-cleansing agents. However, oral bowel-cleansing agents are used more widely in patients undergoing anterior resection and left-sided resections. Postoperative rapid recovery programmes are being increasingly used and usually avoid bowel preparation.

In patients requiring bowel investigation, with comorbidity that may increase the risk of complications from bowel preparation, it is worth considering the role of investigations that require minimal or no formal bowel purgation. CT colonography

with faecal tagging is an area of growing clinical interest and research, using iodinated or barium-based contrast to mark faeces in the colon. It is an effective method of diagnosing and excluding colon cancer and other colonic diseases and potentially avoids the complications of bowel preparation. CT colonography is likely to have an increasingly prominent role in the future, particularly if bowel purgation can be avoided.

Gastrografin is commonly used for small-bowel studies (eg, the investigation of postoperative ileus) and sometimes for CT colonography. It is hyperosmolar and, when used undiluted and/or with high doses, may cause an osmotic diarrhoea. Recommendations on its use are beyond the scope of these guidelines, but clinicians should be aware of the potential risk of causing hypovolaemia.

Finally, these guidelines are intended to reduce the risk of complications from the use of oral bowel-cleansing agents, but they do not address every situation and are not a substitute for sound clinical judgement.

AN INDEX OF THE RECOMMENDATIONS

1. Absolute contraindications to the use of oral bowel-cleansing agents.
2. The choice of oral bowel-cleansing agent.
3. The administration of oral bowel-cleansing agents.
4. Relative contraindications: circumstances in which the choice of a particular oral bowel-cleansing agent or administration protocol may confer significant benefits.
 - 4.1. Chronic kidney disease
 - 4.2. Haemodialysis patients
 - 4.3. Peritoneal dialysis patients
 - 4.4. Renal transplant patients
 - 4.5. Congestive cardiac failure
 - 4.6. Liver cirrhosis and/or ascites
 - 4.7. Patients taking particular medications
 - Renin–angiotensin blockers
 - Diuretics
 - NSAIDs
5. Areas in which further research is needed.

RECOMMENDATIONS

The following conditions are absolute contraindications to the use of all oral bowel-cleansing preparations.

- ▶ Gastrointestinal obstruction or perforation, ileus or gastric retention
 - ▶ Severe acute inflammatory bowel disease or toxic megacolon
 - ▶ Reduced levels of consciousness
 - ▶ Hypersensitivity to any of the ingredients
 - ▶ Inability to swallow without aspiration (in this situation a nasogastric tube may be used for administration)
 - ▶ Ileostomy
- Evidence: grade 1D.

The choice of oral bowel-cleansing agent

The choice of oral bowel-cleansing agent requires consideration of the particular indication, the individual recipient, and the advantages and disadvantages (eg, tolerability, efficacy and potential adverse effects) of the different preparations available. Although oral sodium phosphate preparations are often well tolerated and effective, and are generally safe,^{8–12} the following recommendations are intended to reflect first a concern that adverse outcomes of greater severity may occur more commonly

with these agents, and second that particular patient groups appear to be more at risk of such complications.

Magnesium salt preparations are relatively contraindicated in patients with stage 4 and 5 chronic kidney disease (see online appendix 3 for the definition of chronic kidney disease) (evidence: grade 2D).

Sodium picosulphate preparations should be used with caution in patients at risk of, or suffering from, hypovolaemia, including those patients taking high-dose diuretics, those with congestive cardiac failure and advanced cirrhosis, and those with chronic kidney disease (evidence: grade 1C).

The use of oral sodium phosphate preparations is strongly discouraged in patients with chronic kidney disease, pre-existing electrolyte disturbances, congestive cardiac failure or cirrhosis, or with a history of hypertension (evidence: grade 1C).

The use of oral sodium phosphate preparations in otherwise healthy patients is currently acceptable in cases where sodium picosulphate, magnesium salts and polyethylene glycols have proven ineffective or intolerable (evidence: grade 2C).

The administration of oral bowel-cleansing agents

The appropriate doses of oral bowel-cleansing preparations should not be exceeded (evidence: grade 1C)

Where sodium phosphate preparations are prescribed, modification of the standard dose (two 45 ml doses 9–12 h apart) to a 45 ml dose followed by a 30 ml dose should be considered (evidence: grade 1C). The latter regimen provides equally effective bowel cleansing, but a significantly lower serum phosphate level.⁵³ Furthermore, increasing the interval between doses to 24 h reduces the incidence of clinically relevant hyperphosphataemia (>2.1 mmol/l) without compromising efficacy.⁵⁴ This lengthened preparation process may, however, be more disruptive and less acceptable to patients. Therefore, when sodium phosphate preparations are being administered, a regimen of a 45 ml dose followed by a 30 ml dose 24 h later should be considered (evidence: grade 2C).

The period of bowel cleansing should not normally exceed 24 h (evidence: grade 1C)

To improve both tolerability and efficacy, consideration should be given to splitting the dose of oral bowel-cleansing agent over 12 h when polyethylene glycol preparations are used. This may not be necessary when Moviprep is used because of the lower volume of fluid ingested (evidence: grade 2B).

Hypovolaemia must be corrected before administration of oral bowel-cleansing preparations (evidence: grade 1C)

Patients with comorbidities indicating a predisposition to hypovolaemia should be assessed before starting administration of oral bowel-cleansing agents. Patients at particular risk of hypovolaemia include (but are not limited to) those with chronic or severe diarrhoea, chronic vomiting, dysphagia and persistent hyperglycaemia and those taking high-dose diuretics (see below). Admission to hospital for prehydration may be necessary (evidence: grade 2D).

Where intravenous fluid replacement is undertaken, isotonic fluid (eg, Hartmann's solution) may be preferable⁵⁵ (evidence: grade 2D).

Hypovolaemia must be prevented during administration of oral bowel-cleansing preparations (evidence: grade 1C)

Patients should receive clear instructions regarding oral fluid intake (including an appropriate volume) and these instructions should also be provided in writing (evidence: grade 1D).

Some patients receiving polyethylene glycol may achieve adequate bowel preparation without consuming the full 4 litres of fluid that are generally suggested.⁵⁶ It is reasonable to advise patients to discontinue the oral bowel-cleansing agent if their bowel motions become watery and clear. Intake of other fluids should, however, continue until 2 h before the procedure (evidence: grade 2C).

Isotonic electrolyte oral rehydration solutions may be of benefit,^{37 57} and should be considered in place of high water intake for patients at risk of hyponatraemia being prescribed sodium picosulphate or sodium phosphate (evidence: grade 2C).

Admission for intravenous fluid replacement should be considered in all patients who may be unable to maintain adequate oral intake at home (eg, older patients and those with reduced mobility) (evidence: grade 1C).

If no recent measurement of kidney function is available (within 3 months), kidney function should be measured (using an estimated GFR from serum creatinine concentration) as recommended by NICE, in patients with any of the known conditions listed below

- ▶ Diabetes
- ▶ Hypertension
- ▶ Cardiovascular disease (ischaemic heart disease, chronic heart failure, peripheral vascular disease and cerebral vascular disease)
- ▶ Structural renal tract disease, renal calculi or prostatic hypertrophy
- ▶ Multisystem diseases with potential kidney involvement (eg, systemic lupus erythematosus)
- ▶ Family history of stage 5 chronic kidney disease or hereditary kidney disease
- ▶ Haematuria or proteinuria
- ▶ (See NICE CG73 Chronic Kidney Disease)
- ▶ Evidence: grade 1C

Where a polyethylene glycol preparation is used, renal function tests remain preferable if the above conditions are present, although polyethylene glycol preparations can be used in patients with renal impairment. The renal function tests and electrolytes may, however, be useful in assessing hydration status.

Advice regarding regular medications

Patients should be advised that their regular oral medications should not be taken 1 h before or after administration of bowel-cleansing preparations because of the possibility of impaired absorption (evidence: grade 1C).

Patients taking the oral contraceptive pill should be advised to take alternative precautions during the week after the administration of the oral bowel-cleansing agent (evidence: grade 1C).

Patients in whom the possibility of a reduction in the absorption of their regular medications may prove catastrophic (eg, patients taking immunosuppression for transplants) may require admission for the administration of intravenous medications (evidence: grade 2D).

Patients with diabetes mellitus receiving treatment with insulin will also require specific advice, which should be agreed locally so as to be consistent with local practice and guidance for management of diabetes mellitus while 'nil by mouth' or on reduced oral intake.

Relative contraindications to the use of oral bowel-cleansing preparations: circumstances in which the choice of a particular oral bowel-cleansing agent or administration protocol may confer significant benefits

Polyethylene glycol is safer than sodium phosphate preparations for patients with electrolyte or fluid imbalances in conditions

such as chronic kidney disease, congestive heart failure and liver failure.

Moviprep requires a smaller total volume of fluid (2 litres) to be consumed than Klean Prep (4 litres) and may be preferable in patients in whom the ability to ingest high volumes of fluid causes concern.

Chronic kidney disease

Knowledge of an individual's excretory renal function is an important consideration when identifying the most appropriate oral bowel-cleansing preparation. Pre-existing chronic kidney disease (sometimes unrecognised) is the single most important factor in the development of acute phosphate nephropathy in patients receiving oral sodium phosphate preparations.

Patients with pre-existing electrolyte imbalances should not receive oral sodium phosphate preparations (evidence: grade 1C).

For patients with early chronic kidney disease (stages 1–3 (see appendix 3)), polyethylene glycols, Picolax/Citrafleet and Citramag are all acceptable oral bowel-cleansing agents. It is better to avoid sodium phosphate (evidence: grade 1C).

Patients with stage 3, 4 or 5 chronic kidney disease (an estimated GFR <60 ml/min/1.73 m²) should not receive oral sodium phosphate preparations (evidence: grade 1C).

Polyethylene glycol preparations may be preferable for those patients with stage 4 or 5 chronic kidney disease, who are not receiving dialysis, and who are expected to be able to tolerate the ingestion of the larger volumes of fluid required with these agents. Moviprep requires a smaller total volume of fluid (2 litres) to be consumed than Klean Prep (4 litres) and may be preferable in these patients (evidence: grade 1D).

In patients with stage 4 chronic kidney disease, the use of Picolax/Citrafleet or Citramag is associated with a small risk of magnesium accumulation and should therefore be reserved for those patients likely to be unable to tolerate the ingestion of the volume of fluid required to administer polyethylene glycol preparations (evidence: grade 2D).

In patients with stage 5 chronic kidney disease, who are not receiving haemodialysis, the use of Picolax/Citrafleet is associated with a small risk of magnesium accumulation and should therefore be reserved for those patients likely to be unable to tolerate the ingestion of the volume of fluid required to administer polyethylene glycol preparations (evidence: grade 2D).

Owing to the possibility of magnesium accumulation, the use of Citramag should be avoided in patients with stage 5 chronic kidney disease who are not receiving haemodialysis (evidence: grade 1D).

It should be noted that Klean Prep is currently the only oral bowel-cleansing agent available in the UK that is not contraindicated in chronic kidney disease in the summary of product characteristics.

Chronic haemodialysis

Although acute kidney injury is rarely a concern in these patients, the possibility of intravascular depletion secondary to oral bowel-cleansing agents has other implications in patients receiving chronic haemodialysis. First, there is a risk of dialysis access thrombosis in patients dialysing through arteriovenous fistulae or polytetrafluoroethylene (PTFE) grafts, where a period of intravascular depletion causes hypotension. Second, the combination of dialysis (which is itself often associated with significant fluid and electrolyte shifts) and administration of oral bowel-cleansing agents may provoke more profound hypovolaemia than would otherwise occur. Furthermore, the signifi-

cant oral fluid intake required with polyethylene glycol preparations may provoke fluid overload in anuric patients. For these reasons, each case should be considered on an individual basis, and the timing of dialysis sessions should be tailored to the situation. Admission to hospital for coordination and overseeing of dialysis prescription and administration of oral bowel-cleansing agents may be necessary for some patients receiving chronic haemodialysis (evidence: grade 2D).

Although contraindicated in stage 4 and 5 chronic kidney disease in predialysis patients, sodium picosulphate and magnesium salts can be used safely as oral bowel-cleansing agents in patients receiving haemodialysis (evidence: grade 2D).

Peritoneal dialysis

Peritoneal dialysis is generally associated with less significant fluid shifts than haemodialysis. Admission to hospital for administration of oral bowel-cleansing agents is therefore less likely to be necessary for the majority of patients undergoing peritoneal dialysis. However, a small proportion of these patients have a small but important degree of residual native renal function. This must be assessed on an individual basis. Measures to avoid significant fluid shifts and possible intravascular volume depletion are therefore important in this group. Admission to hospital for overseeing of administration of oral bowel-cleansing agents should be considered in those considered to have important residual renal function (evidence: grade 2D).

Patients undertaking peritoneal dialysis should continue to dialyse in the normal way during the administration of the oral bowel-cleansing agent. The dialysis fluid should be drained out before the procedure for which the bowel preparation has been prescribed.

Renal transplant recipients

These patients should not receive sodium phosphate preparations unless all the alternative agents are contraindicated (evidence: grade 1D).

Admission to hospital may be advisable on an individual patient basis when concerns exist over the absorption of immunosuppressants during concomitant administration of oral bowel-cleansing agents (evidence: grade 2D).

Congestive cardiac failure

Congestive cardiac failure is associated with a reduction in renal blood flow and an associated fall in GFR; the ability of these patients to excrete a phosphate load is therefore reduced, leading to an increased risk of acute phosphate nephropathy. Furthermore, these patients are at particular risk of hyponatraemia caused by the combination of hypovolaemia and high water intake.

Polyethylene glycol preparations are the preferred oral bowel-cleansing agents in patients with congestive cardiac failure (evidence: grade 2D).

Patients with significant congestive cardiac failure (New York Heart Association class III or IV, or an ejection fraction below 50%) should not receive oral sodium phosphate preparations (evidence: grade 1C).

Many medications commonly prescribed to treat heart failure require evaluation before administration of an oral bowel-cleansing agent. For example, where possible, diuretics, ACE inhibitors and angiotensin II receptor blockers should be discontinued in accordance with the guidance below.

Liver cirrhosis and/or ascites

Cirrhosis has been identified as a possible risk factor for acute phosphate nephropathy. Polyethylene glycol is the preferred oral

bowel-cleansing agent for use in patients with liver cirrhosis or ascites (evidence: grade 2D).

Certain medications

ACE inhibitors and angiotensin II receptor blockers

An increase in efferent glomerular arteriolar tone is an important physiological response to hypotension and/or volume depletion, enabling the GFR to be maintained. In the presence of ACE inhibition, this compensatory response is ameliorated. Patients established on ACE inhibitors and angiotensin II receptor blockers are prone to deterioration in renal function during periods of hypovolaemia (eg, precipitated by oral bowel-cleansing agents).

Furthermore, renin–angiotensin blockers also accentuate bicarbonaturia through inhibition of angiotensin II, enhancing alkalisation of the urine. This promotes calcium and phosphate precipitation, increasing the risk of acute phosphate nephropathy in the presence of oral sodium phosphate preparations.⁵⁸

These drug effects may only pose a theoretical risk in many patients, but, where possible, renin–angiotensin blockers should be discontinued on the day of administration of oral bowel-cleansing agents and not reinstated until 72 h after the procedure (evidence: grade 2D).

Diuretics

Diuretics may alter electrolyte balance and predispose to intravascular volume depletion especially in high doses. Therefore it is advised that hydration status is assessed before administration of oral bowel-cleansing preparations in patients taking diuretics. This should include measurement of estimated GFR, but could also include clinical parameters. Low blood pressure, a fall in blood pressure on standing, dry axillae, and reduced jugular venous pressure may indicate fluid depletion, but dry mouth and reduced skin turgor can be misleading.

Unless there is judged to be a significant risk of pulmonary oedema, diuretics should be temporarily discontinued on the day of the administration of oral bowel-cleansing preparation (evidence: grade 1D).

If diuretics are continued, it is important to check electrolytes, use a polyethylene glycol preparation, and advise the patient to avoid dehydration.

Non-steroidal anti-inflammatory drugs

These medications reduce renal perfusion and therefore limit the kidneys' capacity to compensate for reduced renal perfusion through volume depletion. Where possible therefore NSAIDs should be discontinued on the day of administration of oral bowel-cleansing preparations and withheld until 72 h after the procedure (evidence: grade 1D).

Once daily, low-dose aspirin is commonly prescribed to patients with cardio- or cerebro-vascular disease. This medication may reasonably be continued during the administration of oral bowel-cleansing agents (evidence: Grade 1D).

Medications known to induce the syndrome of inappropriate anti-diuretic hormone secretion

These medications increase the risk of water retention and/or electrolyte imbalance, and include tricyclic antidepressants, selective serotonin reuptake inhibitors, many antipsychotic drugs and carbamazepine. While these medications need not be discontinued, serum urea and electrolytes should be checked before administration of oral bowel-cleansing preparations in patients taking them (evidence: grade 2D). The online appen-

dices include a suggested template for a patient advice sheet (appendix 4) and a checklist which may help to identify the most appropriate bowel cleansing agent for any given patient (appendix 5).

AREAS REQUIRING FURTHER RESEARCH

Should the serum creatinine concentration be rechecked after a patient has received oral sodium phosphate, and when should this be undertaken?

Best practice remains unclear. Identification at a later date of non-progressive chronic kidney disease in a typical patient who has developed acute phosphate nephropathy (an older person with hypertension and minimal proteinuria) is unlikely to provide a strong indication for renal biopsy; the link between oral bowel-cleansing preparation and renal impairment is less likely to be noticed as time elapses. A decision not to check the serum creatinine concentration after oral sodium phosphate preparations may lead to cases of acute phosphate nephropathy being missed. This may result in the patient receiving further sodium phosphate preparations. The optimal timing of such a blood test has not been established. Furthermore, it is unclear whether it should be undertaken in all patients receiving oral sodium phosphate preparations or simply those at higher risk of acute phosphate nephropathy. A cost–benefit analysis is also required.

How safe is the use of oral sodium phosphate preparations in patients without those comorbidities currently identified as risk factors for acute phosphate nephropathy?

Given the current evidence base,^{59–61} and their superior tolerability, the use of oral sodium phosphate preparations as oral bowel-cleansing agents in patients without chronic kidney disease, congestive heart failure or liver failure probably remains acceptable. However, further studies are required to ascertain the true safety of sodium phosphate preparations as bowel-cleansing preparations for screening investigations (which, by their nature, are often repeated over time) and in patients with very early (stage 1 or 2) chronic kidney disease.

In the presence of predisposing conditions such as heart failure, what is the risk of acute electrolyte disorders with each preparation?

Hyponatraemia appears most likely to occur when predisposed patients drink large volumes of water, causing water intoxication as a result of overenthusiastic adherence to advice to drink 'plenty of water'. Use of polyethylene glycol preparations involves ingestion of up to 4 litres of fluid, but this is as an isotonic solution and, as such, is designed not to cause electrolyte abnormalities. However, how effective these preparations are at preventing electrolyte disorders requires further study.

Contributors All the stated authors took part in writing and editing the manuscript and have approved the final version.

Competing interests DT has spoken at sponsored meetings since the guidelines were published in draft form, but the purpose of the meetings was to explain the guidelines to clinicians. None of the authors were involved with sponsored meetings during the preparation of these guidelines.

Provenance and peer review Not commissioned; externally peer reviewed.

REFERENCES

1. <http://www.npsa.nhs.uk/nrls/alerts-and-directives/rapidrr/reducing-risk-of-harm-from-oral-bowel-cleansing-solutions> (accessed May 2009).
2. **Wexner SD**, Beck DE, Baron TH, *et al*; American Society of colon and Rectal Surgeons; American Society for gastrointestinal Endoscopy; Society of American gastrointestinal and endoscopic Surgeons. A consensus document on bowel preparation before colonoscopy: prepared by a task force from the American Society of Colon and Rectal Surgeons (ASCRS), the American Society for gastrointestinal

- Endoscopy (ASGE), and the Society of American gastrointestinal and Endoscopic Surgeons (SAGES). *Gastrointest Endosc* 2006;**63**:894–909.
3. **Guyatt GH**, Oxman AD, Kunz R, *et al*. Going from evidence to recommendations. *BMJ* 2008;**336**:1049–51.
 4. **Jaeschke R**, Guyatt GH, Dellinger P, *et al*. Use of GRADE grid to reach decisions on clinical practice guidelines when consensus is elusive. *BMJ* 2008;**337**:a744.
 5. *British National Formulary*, London: BMJ Publishing Group Ltd and Royal Pharmaceutical Society of Great Britain, 2009.
 6. **El Sayed AM**, Kanafani ZA, Mourad FH, *et al*. A randomized single-blind trial of whole versus split-dose polyethylene glycol-electrolyte solution for colonoscopy preparation. *Gastrointest Endosc* 2003;**58**:36–40.
 7. **Schiller LR**. Clinical pharmacology and use of laxatives and lavage solutions. *J Clin Gastroenterol* 1999;**28**:11–18.
 8. **Vanner SJ**, MacDonald PH, Paterson WG, *et al*. A randomized prospective trial comparing oral sodium phosphate with standard polyethylene glycol-based lavage solution (Golytely) in the preparation of patients for colonoscopy. *Am J Gastroenterol* 1990;**85**:422–7.
 9. **Hsu CW**, Imperiale TF. Meta-analysis and cost comparison of polyethylene glycol lavage versus sodium phosphate for colonoscopy preparation. *Gastrointest Endosc* 1998;**48**:276–82.
 10. **Cohen SM**, Wexner SD, Binderow SR, *et al*. Prospective, randomized, endoscopic-blinded trial comparing precolonoscopy bowel cleansing methods. *Dis Colon Rectum* 1994;**37**:689–96.
 11. **Frommer D**. Cleansing ability and tolerance of three bowel preparations for colonoscopy. *Dis Colon Rectum* 1997;**40**:100–4.
 12. **Kolts BE**, Lyles WE, Achem SR, *et al*. A comparison of the effectiveness and patient tolerance of oral sodium phosphate, castor oil, and standard electrolyte lavage for colonoscopy or sigmoidoscopy preparation. *Am J Gastroenterol* 1993;**88**:1218–23.
 13. **Belsey J**, Crosta C, Epstein O, *et al*. Meta-analysis: the relative efficacy of oral bowel preparations for colonoscopy 1985–2010. *Aliment Pharmacol Ther* 2012;**35**:222–37.
 14. **Nelson DB**, Barkun AN, Block KP, *et al*. Technology status evaluation report. Colonoscopy preparations. *Gastrointest Endosc* 2001;**54**:829–32.
 15. **Hoy SM**, Scott LJ, Wagstaff AJ. Sodium picosulfate/magnesium citrate: a review of its use as a colorectal cleanser. *Drugs* 2009;**69**:123–36.
 16. **Miki P Jr**, Lemos CR, Popoutchi P, *et al*. Comparison of colon-cleansing methods in preparation for colonoscopy—comparative efficacy of solutions of mannitol, sodium picosulfate and monobasic and dibasic sodium phosphates. *Acta Cir Bras* 2008;**23** (Suppl 1):108–11.
 17. **Renaut AJ**, Raniga S, Frizelle FA, *et al*. A randomized controlled trial comparing the efficacy and acceptability of phosfo-soda buffered saline (Fleet) with sodium picosulfate/magnesium citrate (Picoprep) in the preparation of patients for colonoscopy. *Colorectal Dis* 2008;**10**:503–5.
 18. **Tjandra JJ**, Chan M, Tagkalidis PP. Oral sodium phosphate (Fleet) is a superior colonoscopy preparation to Picoprep (sodium picosulfate-based preparation). *Dis Colon Rectum* 2006;**49**:616–20.
 19. **Schmidt LM**, Williams P, King D, *et al*. Picoprep-3 is a superior colonoscopy preparation to Fleet: a randomized, controlled trial comparing the two bowel preparations. *Dis Colon Rectum* 2004;**47**:238–42.
 20. **Yoshioka K**, Connolly AB, Ogunbiyi OA, *et al*. Randomized trial of oral sodium phosphate compared with oral sodium picosulfate (Picolax) for elective colorectal surgery and colonoscopy. *Dig Surg* 2000;**17**:66–70.
 21. **Hamilton D**, Mulcahy D, Walsh D, *et al*. Sodium picosulfate compared with polyethylene glycol solution for large bowel lavage: a prospective randomized trial. *Br J Clin Pract* 1996;**50**:73–5.
 22. **Macleod AJ**, Duncan KA, Pearson RH, *et al*. A comparison of fleet Phosfo-soda with Picolax in the preparation of the colon for double contrast barium enema. *Clin Radiol* 1998;**53**:612–14.
 23. **Taylor SA**, Halligan S, Goh V, *et al*. Optimizing bowel preparation for multidetector row CT colonography: effect of Citramag and Picolax. *Clin Radiol* 2003;**58**:723–32.
 24. **Lai AK**, Kwok PC, Man SW, *et al*. A blinded clinical trial comparing conventional cleansing enema, Pico-salax and Golytely for barium enema bowel preparation. *Clin Radiol* 1996;**51**:566–9.
 25. **Swarbrick MJ**, Collins MC, Moore DJ, *et al*. A comparative trial of magnesium citrate (Citramag) and Picolax for barium enema bowel preparation. *Clin Radiol* 1994;**49**:379–81.
 26. **Mc Laughlin P**, Eustace J, Mc Sweeney S, *et al*. Bowel preparation in CT colonography: electrolyte and renal function disturbances in the frail and elderly patient. *Eur Radiol* 2010;**20**:604–12.
 27. **Bowles CJ**, Leicester R, Romaya C, *et al*. A prospective study of colonoscopy practice in the UK today: are we adequately prepared for national colorectal cancer screening tomorrow? *Gut* 2004;**53**:277–83.
 28. **Vradelis S**, Kalaitzakis E, Sharifi Y, *et al*. Addition of senna improves quality of colonoscopy preparation with magnesium citrate. *World J Gastroenterol* 2009;**15**:1759–63.
 29. **Kastenbergh D**, Chasen R, Choudhary C, *et al*. Efficacy and safety of sodium phosphate tablets compared with PEG solution in colon cleansing: two identically designed, randomized, controlled, parallel group multicenter phase III trials. *Gastrointest Endosc* 2001;**54**:705–13.
 30. **Eschinger EJ**, Littman JJ, Meyer K, *et al*. Safety of sodium phosphate tablets in patients receiving propofol-based sedation for colonoscopy. *J Clin Gastroenterol* 2004;**38**:425–8.
 31. **Reddy DN**, Rao GV, Sriram PV. Efficacy and safety of oral sodium phosphate versus polyethylene glycol solution for bowel preparation for colonoscopy. *Indian J Gastroenterol* 2002;**21**:219–21.
 32. **Brunelli SM**, Feldman HI, Latif SM, *et al*. A comparison of sodium phosphosoda purgative to polyethylene glycol bowel preparations prior to colonoscopy. *Fam Med* 2009;**41**:39–45.
 33. **Beloosesky Y**, Grinblat J, Weiss A, *et al*. Electrolyte disorders following oral sodium phosphate administration for bowel cleansing in elderly patients. *Arch Intern Med* 2003;**163**:803–8.
 34. **Ainley EJ**, Winwood PJ, Begley JP. Measurement of serum electrolytes and phosphate after sodium phosphate colonoscopy bowel preparation: an evaluation. *Dig Dis Sci* 2005;**50**:1319–23.
 35. **Ho JM**, Juurlink DN, Cavalcanti RB. Hypokalemia following polyethylene glycol-based bowel preparation for colonoscopy in older hospitalized patients with significant comorbidities. *Ann Pharmacother* 2010;**44**:466–70.
 36. **Lien YH**. Is bowel preparation before colonoscopy a risky business for the kidney? *Nat Clin Pract Nephrol* 2008;**4**:606–14.
 37. **Tjandra JJ**, Tagkalidis P. Carbohydrate-electrolyte (E-Lyte) solution enhances bowel preparation with oral fleet phospho-soda. *Dis Colon Rectum* 2004;**47**:1181–6.
 38. **Frizelle FA**, Colls BM. Hyponatremia and seizures after bowel preparation: report of three cases. *Dis Colon Rectum* 2005;**48**:393–6.
 39. **Nagler J**, Poppers D, Turetz M. Severe hyponatremia and seizure following a polyethylene glycol-based bowel preparation for colonoscopy. *J Clin Gastroenterol* 2006;**40**:558–9.
 40. **Nyberg C**, Hendel J, Nielsen OH. The safety of osmotically acting cathartics in colonic cleansing. *Nat Rev Gastroenterol Hepatol* 2010;**7**:557–64.
 41. **Markowitz GS**, Radhakrishnan J, D'Agati VD. Towards the incidence of acute phosphate nephropathy. *J Am Soc Nephrol* 2007;**18**:3020–2.
 42. **Markowitz GS**, Stokes MB, Radhakrishnan J, *et al*. Acute phosphate nephropathy following oral sodium phosphate bowel purgative: an underrecognized cause of chronic renal failure. *J Am Soc Nephrol* 2005;**16**:3389–96.
 43. **Gumurdulu Y**, Serin E, Ozer B, *et al*. Age as a predictor of hyperphosphataemia after oral phosphosoda administration for colon preparation. *J Gastroenterol Hepatol* 2004;**19**:68–72.
 44. **Hookey LC**, Vanner S. Recognizing the clinical contraindications to the use of oral sodium phosphate for colon cleansing: a case study. *Can J Gastroenterol* 2004;**18**:455–8.
 45. **Brunelli SM**, Lewis JD, Gupta M, *et al*. Risk of kidney injury following oral phosphosoda bowel preparations. *J Am Soc Nephrol* 2007;**18**:3199–205.
 46. **Sica DA**, Carl D, Zfass AM. Acute phosphate nephropathy—an emerging issue. *Am J Gastroenterol* 2007;**102**:1844–7.
 47. **Food and Drug Administration**. *Oral Sodium Phosphate (OSP) Products for Bowel Cleansing*. 2006. http://www.fda.gov/cder/drug/infopage/osp_solution (accessed 11 May 2009).
 48. **Kontani M**, Hara A, Ohta S, *et al*. Hypermagnesemia induced by massive cathartic ingestion in an elderly woman without pre-existing renal dysfunction. *Intern Med* 2005;**44**:448–52.
 49. **Onishi S**, Yoshino S. Cathartic-induced fatal hypermagnesemia in the elderly. *Intern Med* 2006;**45**:207–10.
 50. **Schelling JR**. Fatal hypermagnesemia. *Clin Nephrol* 2000;**53**:61–5.
 51. **Jung B**, Pählman L, Nyström PO; Mechanical Bowel Preparation Study Group. Multicentre randomized clinical trial of mechanical bowel preparation in elective colonic resection. *Br J Surg* 2007;**94**:689–95.
 52. **Contant CM**, Hop WC, van't Sant HP, *et al*. Mechanical bowel preparation for elective colorectal surgery: a multicentre randomised trial. *Lancet* 2007;**370**:2112–17.
 53. **Rex DK**. Dosing considerations in the use of sodium phosphate bowel preparations for colonoscopy. *Ann Pharmacother* 2007;**41**:1466–75.
 54. **Rostom A**, Jolicoeur E, Dubé C, *et al*. A randomized prospective trial comparing different regimens of oral sodium phosphate and polyethylene glycol-based lavage solution in the preparation of patients for colonoscopy. *Gastrointest Endosc* 2006;**64**:544–52.
 55. **Powell-Tuck J**, Gosling P, Lobo DN, *et al*. *British Consensus Guidelines on Intravenous Fluid Therapy for Adult Surgical Patients*. GIFTASUP. http://www.renal.org/pages/media/Guidelines/GIFTASUP%20FINAL_31-10-08.pdf (accessed 10 Aug 2009).
 56. **Vilien M**, Rytönen M. Golytely preparation for colonoscopy: 1.5 liters is enough for outpatients. *Endoscopy* 1990;**22**:168–70.
 57. **Barclay RL**, Depew WT, Vanner SJ. Carbohydrate-electrolyte rehydration protects against intravascular volume contraction during colonic cleansing with orally administered sodium phosphate. *Gastrointest Endosc* 2002;**56**:633–8.
 58. **Beyea A**, Block C, Schned A. Acute phosphate nephropathy following oral sodium phosphate solution to cleanse the bowel for colonoscopy. *Am J Kidney Dis* 2007;**50**:151–4.
 59. **Russmann S**, Lamerato L, Marfatia A, *et al*. Risk of impaired renal function after colonoscopy: a cohort study in patients receiving either oral sodium phosphate or polyethylene glycol. *Am J Gastroenterol* 2007;**102**:2655–63.
 60. **Singal AK**, Rosman AS, Post JB, *et al*. The renal safety of bowel preparations for colonoscopy: a comparative study of oral sodium phosphate solution and polyethylene glycol. *Aliment Pharmacol Ther* 2008;**27**:41–7.
 61. **Hurst FP**, Bohem EM, Osgard EM, *et al*. Association of oral sodium phosphate purgative use with acute kidney injury. *J Am Soc Nephrol* 2007;**18**:3192–8.

APPENDIX 1: THE MODIFIED GRADE SYSTEM

| Grade of Recommendation | Clarity of risk/benefit | Quality of supporting evidence | Implications for clinical practice |
|---|---|--|---|
| 1A Strong recommendation. High quality evidence. | Benefits clearly outweigh risk and burdens, or vice versa | Consistent evidence from well performed randomized, controlled trials or overwhelming evidence of some other form. Further research is unlikely to change our confidence in the estimate of benefit and risk. | Strong recommendations, can apply to most patients in most circumstances without reservation. Clinicians should follow a strong recommendation unless there is a clear rationale for an alternative approach. |
| 1B Strong recommendation. Moderate quality evidence. | Benefits clearly outweigh risk and burdens, or vice versa | Evidence from randomized, controlled trials with important limitations (inconsistent results, methods flaws, indirect or imprecise), or very strong evidence of some other research design. Further research may impact on our confidence in the estimate of benefit and risk. | Strong recommendation and applies to most patients. Clinicians should follow a strong recommendation unless a clear and compelling rationale for an alternative approach is present. |
| 1C Strong recommendation. Low quality evidence. | Benefits appear to outweigh risk and burdens, or vice versa | Evidence from observational studies, unsystematic clinical experience, or from randomized, controlled trials with serious flaws. Any estimate of effect is uncertain. | Strong recommendation, and applies to most patients. Some of the evidence base supporting the recommendation is, however, of low quality. |
| 1D Strong recommendation Very low quality evidence | Benefits appear to outweigh risk and burdens, or vice versa | Evidence limited to case studies | Strong recommendation based mainly on case studies and expert judgement |
| 2A Weak recommendation. High quality evidence. | Benefits closely balanced with risks and burdens | Consistent evidence from well performed randomized, controlled trials or overwhelming evidence of some other form. Further research is unlikely to change our confidence in the estimate of benefit and risk. | Weak recommendation, best action may differ depending on circumstances or patients' or societal values |
| 2B Weak recommendation. Moderate quality evidence. | Benefits closely balanced with risks and burdens, some uncertainty in the estimates of benefits, risks and burdens | Evidence from randomized, controlled trials with important limitations (inconsistent results, methods flaws, indirect or imprecise), or strong evidence of some other research design. Further research may change the estimate of benefit and risk. | Weak recommendation, alternative approaches likely to be better for some patients under some circumstances |
| 2C Weak recommendation. Low quality evidence. | Uncertainty in the estimates of benefits, risks, and burdens; benefits may be closely balanced with risks and burdens | Evidence from observational studies, unsystematic clinical experience, or from randomized, controlled trials with serious flaws. Any estimate of effect is uncertain. | Weak recommendation; other alternatives may be reasonable |
| 2D Weak recommendation Very low quality evidence | Uncertainty in the estimates of benefits, risks, and burdens; benefits may be closely balanced with risks and burdens | Evidence limited to case studies and expert judgement | Very weak recommendation; other alternatives may be equally reasonable. |

APPENDIX 2: COMMENTS REGARDING POTENTIAL ADVANTAGES AND COMPLICATIONS OF INDIVIDUAL ORAL BOWEL CLEANSING AGENTS

| Oral Bowel Cleansing Agent (OBCA) | Potential advantages of this OBCA | Tolerability and ease of use | Is a low residue diet advised prior to dosing? | Are there complications specific to this OBCA?* | Are there any contraindications specific to this OBCA?* |
|-----------------------------------|-------------------------------------|------------------------------------|--|---|--|
| Citrafleet® or Picolax® | Produces the lowest watery residue: | Powder is reconstituted with a low | Yes | 1. Higher risk of hyponatraemia (if excessive water | It is particularly important that patients with conditions predisposing to |

| | | | | | |
|--|---|--|---|---|---|
| (Sodium picosulphate & magnesium citrate) | potentially advantageous for radiological investigation. | volume of water. It then arms on mixing. | | ingestion) than with other OBCA's. 2. Risk of hypermagnesaemia in patients with advanced Chronic Kidney Disease. | hypovolaemia are evaluated prior to receiving this OBCA. |
| Citramag[®] (magnesium carbonate and citric acid) | Produces a low watery residue (although not as low as Picolax [®]). | Powder is reconstituted with a low volume of hot water. | Yes. | 1. Higher risk of hyponatraemia (if excessive water ingestion) than with other OBCA's. 2. Risk of hypermagnesaemia in patients with advanced Chronic Kidney Disease. | It is particularly important that patients with conditions predisposing to hypovolaemia are evaluated prior to receiving this OBCA. |
| Klean Prep[®] (polyethylene glycol) | Less likely to cause hypovolaemia. | Powder is reconstituted with a high volume of water (up to 4 litres). | Yes. | <i>Lowest risk of provoking hypovolaemia and/or hyponatraemia.</i> | |
| Moviprep[®] (polyethylene glycol) | Less likely to cause hypovolaemia | Powder is reconstituted with a moderate volume of water (approx 2 litres). | Yes. | <i>Lowest risk of provoking hypovolaemia and/or hyponatraemia.</i> | G6PD deficiency. |
| Fleet Phosphosoda[®] (sodium phosphate) | Well tolerated. | A low volume of liquid (45 mls) is mixed with a low volume of water (120 mls). | No. It is sufficient to simply avoid solid food during the dosing period. | 1. Acute Phosphate Nephropathy. 2. Hypocalcaemia resulting from hyperphosphataemia. 3. Highest risk of hypovolaemia. | Should not be prescribed to patients with; 1. hypovolaemia 2. eGFR < 60 ml/min/1.73m ² 3. hepatic cirrhosis 4. cardiac failure 5. hypertension 6. renin-angiotensin blockade ...unless <i>all</i> other OBCA's are contraindicated. |

It should be remembered that the administration of ALL types of OBCA may be complicated by hypovolaemia and/or electrolyte disturbances (including hypokalaemia, hyponatraemia and hypernatraemia).

⁺ The following are absolute contraindications to ALL types of OBCA: gastrointestinal obstruction, perforation or ileus; severe inflammatory bowel disease; reduced consciousness; hypersensitivity to any of the ingredients; ileostomy.

APPENDIX 3: THE CLASSIFICATION OF CHRONIC KIDNEY DISEASE

The diagnosis of Chronic Kidney Disease (CKD) is based on two parameters. The first is the Glomerular Filtration Rate (GFR). An estimated GFR (eGFR), calculated from the serum creatinine concentration, is commonly employed. To ensure that the impairment in renal function is chronic in nature rather than acute, the GFR should be calculated on two occasions over 90

days apart. The second parameter is the presence of markers of kidney damage, which include abnormalities evident on urinalysis (eg proteinuria) or radiological investigation.

| Stage | Description | GFR mL/min/1.73m² |
|--------------|--|-------------------------------------|
| 1 | Kidney damage evident Normal or elevated GFR | > 90 |
| 2 | Kidney damage evident Mildly reduced GFR | 60 – 89 |
| 3A | Moderately reduced GFR +/- documented kidney damage | 45 – 59 |
| 3B | Moderately reduced GFR +/- documented kidney damage | 44 – 30 |
| 4 | Severely reduced GFR +/- documented kidney damage | 15 – 29 |
| 5 | Kidney Failure +/- documented kidney damage | < 15 or on dialysis |

APPENDIX 4: ORAL BOWEL CLEANSING AGENT PATIENT ADVICE SHEET

The following Patient Advice Sheet is not intended to replace instruction sheets already in existence at a local level. Individual units may wish to use it alongside their existing instruction sheets, or to consider including the information it contains within their existing instruction sheets.

This Patient Advice Sheet provides information that is frequently omitted from the instructions provided by the manufacturers of the oral bowel cleansing agents. It is intended to augment these instructions, not to replace them.

Local contact details should be included on the template to allow patients to raise concerns or uncertainties.

AN ADVICE SHEET FOR PATIENTS WHO HAVE BEEN PRESCRIBED AN ORAL BOWEL CLEANSING AGENT.

You have been prescribed an oral bowel cleansing agent (sometimes also called a 'bowel prep'). Its role is to clear out your bowels. This is important to ensure the safety and success of the planned procedure. There is a risk of developing dehydration, low blood pressure or kidney problems with this medication. The doctor prescribing the oral bowel cleansing agent will have assessed your risk and identified the most appropriate medication for you. You may also have had a blood test to check your kidney function. A number of oral bowel cleansing agents are available. You should refer to the manufacturer's instructions when taking your preparation. However the following rules apply in all cases.

The prescribed dose of oral bowel cleansing agent should not be exceeded. The oral bowel cleansing agent should not usually be taken over a period longer than 24 hours but this can be varied if you have previously had problems achieving a clean bowel with bowel prep.

Oral bowel cleansing agents predispose to dehydration. You should maintain a good fluid intake whilst taking these medications. If you develop the symptoms of dehydration, and cannot increase your fluid intake, then you should seek medical attention. These symptoms include dizziness or lightheadness (particularly on standing up), thirst, or a reduced urine production.

You should follow any specific advice you have been given with regard to your regular medications. Medications that you may have been asked to temporarily discontinue include...

- **antihypertensives** (to lower your blood pressure) such as ACE inhibitors like Ramipril®
- **diuretics** ('water tablets', such as furosemide)
- **non-steroidal anti-inflammatory drugs** (a type of pain killer, such as ibuprofen)
- **iron preparations** (for anaemia, such as ferrous sulphate)
- **aspirin, dipyridamole, clopidogrel or warfarin** (these agents thin your blood; you may have been asked to discontinue them depending on the nature of the procedure that is planned)

If you have not received specific advice regarding your regular medications then you should continue to take them as normal. However, you may need to amend the timing as it is preferable to avoid taking them less than one hour either side of any dose of oral bowel cleansing agent.

Patients taking immunosuppression for transplanted organs should seek the advice of their doctor before taking an oral bowel cleansing agent.

Patients taking the oral contraceptive pill should take alternative precautions during the week following taking the oral bowel cleansing agent.

If you experience problems, advice from a healthcare professional is available on (Tel No).

APPENDIX 5: ORAL BOWEL CLEANSING AGENT PRESCRIPTION CHECKLIST

NAME

HOSPITAL NO.

Date of Birth

ORAL BOWEL CLEANSING AGENT PRESCRIPTION CHECKLIST
 This checklist is to be completed by the clinician authorising the oral bowel cleansing agent and should then be filed in the patient's medical records.

STEP 1: ABSOLUTE CONTRAINDICATIONS

| | |
|--------------------------------------|-------|
| GI Obstruction, ileus or perforation | Y / N |
| Severe IBD | Y / N |
| Toxic megacolon | Y / N |
| Reduced conscious level | Y / N |
| Hypersensitivity to any ingredients | Y / N |
| Dysphagia (unless via NGT) | Y / N |
| Ileostomy | Y / N |

↓
 If yes to any question, do not continue.

STEP 2: REVIEW ANY BLOOD RESULTS
 (Should be checked in patients with comorbidities)

| | | |
|------|-------|--------------------|
| Na | | eGFR 30-60 = CKD 3 |
| K | | eGFR 15-29 = CKD 4 |
| eGFR | | eGFR 0-14 = CKD 5 |

↓

STEP 3: Review MEDICATIONS

| | | | |
|-----------|-----|--------------------------|-----|
| ACEi/ARB | Y/N | Safe to stop for 72 hrs? | Y/N |
| Diuretics | Y/N | Safe to stop for 24 hrs? | Y/N |
| NSAIDs | Y/N | Safe to stop for 72 hrs? | Y/N |

STEP 4: CONSIDER CO-MORBIDITIES & RISK FACTORS

| Comorbidities | Optimal | Acceptable | Avoid |
|------------------------------|------------------------------|----------------------|---------------|
| Kidney Disease | | | |
| CKD 3 | PEG / Pico / CF / Citramag | | OSP |
| CKD 4 | PEG (if fluid status allows) | Pico /CF / Citramag | OSP |
| CKD 5 | PEG (if fluid status allows) | Pico / CF | OSP, Citramag |
| Haemodialysis | Discuss with nephrologist | | |
| Peritoneal dialysis | Discuss with nephrologist | | |
| Renal Transplant | Discuss with nephrologist | | |
| Electrolyte Imbalance | PEG | Pico / CF / Citramag | OSP |
| Cardiac Failure | PEG | Pico / CF / Citramag | OSP |
| Liver Cirrhosis | PEG | Pico / CF | OSP |
| Hypertension | PEG / Pico / CF / Citramag | | OSP |

STEP 5: TYPE OF BOWEL PREP ISSUED?

Picolax / Citrafleet/ Citramag / Klean Prep / Moviprep / Fleet Phospho-soda

STEP 6: INSTRUCTIONS PROVIDED TO THE PATIENT

Verbally Y/N
 Leaflet Y/N

STEP 7: OTHER COMMENTS

↓

STEP 8: SIGNATURE

KEY **ACEi** Angiotensin converting enzyme inhibitors, **ARB** Angiotensin II Receptor Blockers, **CKD** chronic kidney disease,
OSP oral sodium phosphate preparations (Fleet Phospho-soda), **PEG** polyethylene glycol (Klean Prep, Moviprep, Pico Picolax, CF Citrafleet)